Jasper Therapeutics appoints Svetlana Lucas to Board; Anna French resigns

Jasper Therapeutics, Inc.

Anna French resigned from Board effective June 18, 2024, citing no disagreement with company.
Svetlana Lucas, Ph.D., appointed as Class III director effective June 18, 2024.
Lucas is Chief Business Officer at Scribe Therapeutics with 20+ years in biopharma strategy.
Received initial option grant of 15,000 shares at $23.19/share, vesting over 4 years.
Also serves on board of aTyr Pharma (Nasdaq: LIFE) and as advisor to Radar Therapeutics.

item 5.02 item 8.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Anna French

Director

JSPR · Jasper Therapeutics, Inc.

Effective: 2024-06-18
Successor: Svetlana Lucas
Filed: June 20, 2024, 7:59 PM ET

On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.

Appointed

Svetlana Lucas

Class III Director

JSPR · Jasper Therapeutics, Inc.

Effective: 2024-06-18
Filed: June 20, 2024, 7:59 PM ET

Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Anna French resigned as Director at Jasper Therapeutics, Inc..

Action: resigned
Role: Director

Exact text from the filing

On June 17, 2024, Anna French, D.Phil. notified the Board of Directors (the “Board”) of Jasper Therapeutics, Inc. (the “Company”) of her intent to resign from the Board effective as of June 18, 2024.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Svetlana Lucas was appointed as Class III Director at Jasper Therapeutics, Inc..

Action: appointed
Role: Class III Director

Exact text from the filing

Effective immediately following Dr. French’s resignation, on June 18, 2024, the Board appointed Svetlana Lucas, Ph.D. as a Class III director of the Company.

View on SEC.gov

Jasper Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001213900-24-053982

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.